XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss for the period $ (10,211) $ (10,306)
Adjustments for non-cash items:    
Share-based compensation expense 3,614 6,439
Decrease in deferred tax liability (2,930) (444)
Change in fair value of warrant liability (33) (726)
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone 428
Fair value of shares issued for services 90 90
Share of loss in associate 268 363
Foreign exchange transaction gain (15)
Depreciation 1
Changes in operating working capital:    
Accounts receivable 25 385
Prepaid expenses and other receivables (354) 1,286
Other assets 24 (144)
Accounts payable and accrued liabilities 1,671 (1,486)
Other 30 30
Net cash used in operating activities (7,392) (4,513)
Cash flows from investing activities:    
Purchase of convertible note receivable (614)
Purchase of equipment (3)
Net cash used in investing activities (617)
Cash flows from financing activities:    
Repayment of notes payable assumed in Tarus acquisition (2,000)
Repayment of milestone obligation assumed in Tarus acquisition (1,009)
Proceeds from shares issued under ATM and Committed Purchase 794
Proceeds from shares issued under registered offering 29,093
Share issuance costs (24) (1,852)
Proceeds from exercise of stock purchase warrants 105
Net cash (used in) provided by financing activities (2,239) 27,346
(Decrease) increase in cash and cash equivalents during period (10,248) 22,833
Cash and cash equivalents at beginning of period 23,352 2,770
Cash and cash equivalents at end of period 13,104 25,603
Supplemental disclosure of cash flow information:    
Cash paid for interest 19
Increase in accounts payable for stock issuance costs 25
Supplemental disclosure of non-cash investing and financing activities:    
Fair value of shares issued for Tarus 17,200
Fair value of shares issued for non-controlling interest purchase of iOx 9,737
Fair value of deferred purchase price payable-Tarus 8,538
Fair value of deferred obligation - iOx milestone 5,478
Liabilities assumed in Tarus acquisition 3,000
Fair value of shares issued for commitment fees - Committed Purchase 900
Exchange of iOx shares for settlement of notes payable, accrued interest and warrants $ 184